AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
Pharmaceutical Technology on MSN1d
AstraZeneca’s shares rise as it addresses China investigationIn addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, ...
Astrazeneca's revenue jumped 21 per cent last year as the pharmaceutical recorded broad growth across its key businesses.
Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales ...
AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback